Target Gene/Pathway Pathway / Gene
Search results
No. | KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related | KEGG GENES | KEGG DRUG | DrugBank | Disease ID | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Adipocytokine signaling pathway 💬 16 genes, 38 drugs (DrugBank) and 104 diseases |
JAK2 [1] JAK2 💬Adipocytokine signaling pathway
|
Tofacitinib citrate Tofacitinib citrate 💬Adipocytokine signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬1. Adipocytokine signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 | Adipocytokine signaling pathway 💬 16 genes, 38 drugs (DrugBank) and 104 diseases |
JAK2 [1] JAK2 💬Adipocytokine signaling pathway
|
Tofacitinib Tofacitinib 💬Adipocytokine signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬1. Adipocytokine signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 | AGE-RAGE signaling pathway in diabetic complications 💬 28 genes, 55 drugs (DrugBank) and 96 diseases |
JAK2 [1] JAK2 💬AGE-RAGE signaling pathway in diabetic complications
|
Tofacitinib citrate Tofacitinib citrate 💬AGE-RAGE signaling pathway in diabetic complications
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬3. AGE-RAGE signaling pathway in diabetic complications
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 | AGE-RAGE signaling pathway in diabetic complications 💬 28 genes, 55 drugs (DrugBank) and 96 diseases |
JAK2 [1] JAK2 💬AGE-RAGE signaling pathway in diabetic complications
|
Tofacitinib Tofacitinib 💬AGE-RAGE signaling pathway in diabetic complications
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬3. AGE-RAGE signaling pathway in diabetic complications
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 | Chemical carcinogenesis - receptor activation 💬 39 genes, 135 drugs (DrugBank) and 134 diseases |
JAK2 [1] JAK2 💬Chemical carcinogenesis - receptor activation
|
Tofacitinib citrate Tofacitinib citrate 💬Chemical carcinogenesis - receptor activation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬5. Chemical carcinogenesis - receptor activation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | Chemical carcinogenesis - receptor activation 💬 39 genes, 135 drugs (DrugBank) and 134 diseases |
JAK2 [1] JAK2 💬Chemical carcinogenesis - receptor activation
|
Tofacitinib Tofacitinib 💬Chemical carcinogenesis - receptor activation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬5. Chemical carcinogenesis - receptor activation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 | Chemokine signaling pathway 💬 23 genes, 38 drugs (DrugBank) and 64 diseases |
JAK2 [2] JAK2, JAK3 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Chemokine signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬7. Chemokine signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
8 | Chemokine signaling pathway 💬 23 genes, 38 drugs (DrugBank) and 64 diseases |
JAK2 [2] JAK2, JAK3 💬
|
Tofacitinib Tofacitinib 💬Chemokine signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬7. Chemokine signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
9 | Cholinergic synapse 💬 32 genes, 64 drugs (DrugBank) and 81 diseases |
JAK2 [1] JAK2 💬Cholinergic synapse
|
Tofacitinib citrate Tofacitinib citrate 💬Cholinergic synapse
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬9. Cholinergic synapse
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
10 | Cholinergic synapse 💬 32 genes, 64 drugs (DrugBank) and 81 diseases |
JAK2 [1] JAK2 💬Cholinergic synapse
|
Tofacitinib Tofacitinib 💬Cholinergic synapse
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬9. Cholinergic synapse
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
11 | Coronavirus disease - COVID-19 💬 54 genes, 108 drugs (DrugBank) and 105 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Coronavirus disease - COVID-19
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬11. Coronavirus disease - COVID-19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
12 | Coronavirus disease - COVID-19 💬 54 genes, 108 drugs (DrugBank) and 105 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib Tofacitinib 💬Coronavirus disease - COVID-19
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬11. Coronavirus disease - COVID-19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
13 | Efferocytosis 💬 29 genes, 74 drugs (DrugBank) and 93 diseases |
JAK2 [1] JAK2 💬Efferocytosis
|
Tofacitinib citrate Tofacitinib citrate 💬Efferocytosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬13. Efferocytosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
14 | Efferocytosis 💬 29 genes, 74 drugs (DrugBank) and 93 diseases |
JAK2 [1] JAK2 💬Efferocytosis
|
Tofacitinib Tofacitinib 💬Efferocytosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬13. Efferocytosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 | Epstein-Barr virus infection 💬 67 genes, 90 drugs (DrugBank) and 82 diseases |
JAK1 [3] JAK1, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Epstein-Barr virus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬15. Epstein-Barr virus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 | Epstein-Barr virus infection 💬 67 genes, 90 drugs (DrugBank) and 82 diseases |
JAK1 [3] JAK1, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬Epstein-Barr virus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬15. Epstein-Barr virus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
17 | Growth hormone synthesis, secretion and action 💬 23 genes, 49 drugs (DrugBank) and 100 diseases |
JAK2 [1] JAK2 💬Growth hormone synthesis, secretion and action
|
Tofacitinib citrate Tofacitinib citrate 💬Growth hormone synthesis, secretion and action
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬17. Growth hormone synthesis, secretion and action
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
18 | Growth hormone synthesis, secretion and action 💬 23 genes, 49 drugs (DrugBank) and 100 diseases |
JAK2 [1] JAK2 💬Growth hormone synthesis, secretion and action
|
Tofacitinib Tofacitinib 💬Growth hormone synthesis, secretion and action
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬17. Growth hormone synthesis, secretion and action
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
19 | Hepatitis B 💬 43 genes, 65 drugs (DrugBank) and 87 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Hepatitis B
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬19. Hepatitis B
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 | Hepatitis B 💬 43 genes, 65 drugs (DrugBank) and 87 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬Hepatitis B
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬19. Hepatitis B
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
21 | Hepatitis C 💬 36 genes, 70 drugs (DrugBank) and 87 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Hepatitis C
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬21. Hepatitis C
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
22 | Hepatitis C 💬 36 genes, 70 drugs (DrugBank) and 87 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib Tofacitinib 💬Hepatitis C
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬21. Hepatitis C
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
23 | Herpes simplex virus 1 infection 💬 70 genes, 80 drugs (DrugBank) and 107 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Herpes simplex virus 1 infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬23. Herpes simplex virus 1 infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
24 | Herpes simplex virus 1 infection 💬 70 genes, 80 drugs (DrugBank) and 107 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib Tofacitinib 💬Herpes simplex virus 1 infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬23. Herpes simplex virus 1 infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
25 | Hormone signaling 💬 66 genes, 211 drugs (DrugBank) and 153 diseases |
JAK2 [1] JAK2 💬Hormone signaling
|
Tofacitinib citrate Tofacitinib citrate 💬Hormone signaling
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬25. Hormone signaling
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
26 | Hormone signaling 💬 66 genes, 211 drugs (DrugBank) and 153 diseases |
JAK2 [1] JAK2 💬Hormone signaling
|
Tofacitinib Tofacitinib 💬Hormone signaling
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬25. Hormone signaling
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
27 | Human cytomegalovirus infection 💬 64 genes, 114 drugs (DrugBank) and 130 diseases |
JAK1 [1] JAK1 💬Human cytomegalovirus infection
|
Tofacitinib citrate Tofacitinib citrate 💬Human cytomegalovirus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬27. Human cytomegalovirus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
28 | Human cytomegalovirus infection 💬 64 genes, 114 drugs (DrugBank) and 130 diseases |
JAK1 [1] JAK1 💬Human cytomegalovirus infection
|
Tofacitinib Tofacitinib 💬Human cytomegalovirus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬27. Human cytomegalovirus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
29 | Human papillomavirus infection 💬 51 genes, 106 drugs (DrugBank) and 115 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Human papillomavirus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬29. Human papillomavirus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
30 | Human papillomavirus infection 💬 51 genes, 106 drugs (DrugBank) and 115 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib Tofacitinib 💬Human papillomavirus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬29. Human papillomavirus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
31 | Human T-cell leukemia virus 1 infection 💬 59 genes, 74 drugs (DrugBank) and 96 diseases |
JAK1 [2] JAK1, JAK3 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Human T-cell leukemia virus 1 infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬31. Human T-cell leukemia virus 1 infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
32 | Human T-cell leukemia virus 1 infection 💬 59 genes, 74 drugs (DrugBank) and 96 diseases |
JAK1 [2] JAK1, JAK3 💬
|
Tofacitinib Tofacitinib 💬Human T-cell leukemia virus 1 infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬31. Human T-cell leukemia virus 1 infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
33 | Influenza A 💬 65 genes, 78 drugs (DrugBank) and 98 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Influenza A
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬33. Influenza A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
34 | Influenza A 💬 65 genes, 78 drugs (DrugBank) and 98 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib Tofacitinib 💬Influenza A
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬33. Influenza A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
35 | JAK-STAT signaling pathway 💬 61 genes, 113 drugs (DrugBank) and 123 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬JAK-STAT signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬35. JAK-STAT signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
36 | JAK-STAT signaling pathway 💬 61 genes, 113 drugs (DrugBank) and 123 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬JAK-STAT signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬35. JAK-STAT signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
37 | Kaposi sarcoma-associated herpesvirus infection 💬 60 genes, 94 drugs (DrugBank) and 118 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Kaposi sarcoma-associated herpesvirus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬37. Kaposi sarcoma-associated herpesvirus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
38 | Kaposi sarcoma-associated herpesvirus infection 💬 60 genes, 94 drugs (DrugBank) and 118 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib Tofacitinib 💬Kaposi sarcoma-associated herpesvirus infection
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬37. Kaposi sarcoma-associated herpesvirus infection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
39 | Leishmaniasis 💬 40 genes, 68 drugs (DrugBank) and 102 diseases |
JAK1 [2] JAK1, JAK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Leishmaniasis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬39. Leishmaniasis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
40 | Leishmaniasis 💬 40 genes, 68 drugs (DrugBank) and 102 diseases |
JAK1 [2] JAK1, JAK2 💬
|
Tofacitinib Tofacitinib 💬Leishmaniasis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬39. Leishmaniasis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
41 | Lipid and atherosclerosis 💬 51 genes, 71 drugs (DrugBank) and 103 diseases |
JAK2 [1] JAK2 💬Lipid and atherosclerosis
|
Tofacitinib citrate Tofacitinib citrate 💬Lipid and atherosclerosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬41. Lipid and atherosclerosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
42 | Lipid and atherosclerosis 💬 51 genes, 71 drugs (DrugBank) and 103 diseases |
JAK2 [1] JAK2 💬Lipid and atherosclerosis
|
Tofacitinib Tofacitinib 💬Lipid and atherosclerosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬41. Lipid and atherosclerosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
43 | Measles 💬 42 genes, 63 drugs (DrugBank) and 68 diseases |
JAK1 [3] JAK1, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Measles
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬43. Measles
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
44 | Measles 💬 42 genes, 63 drugs (DrugBank) and 68 diseases |
JAK1 [3] JAK1, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬Measles
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬43. Measles
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
45 | Necroptosis 💬 32 genes, 52 drugs (DrugBank) and 77 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Necroptosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬45. Necroptosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
46 | Necroptosis 💬 32 genes, 52 drugs (DrugBank) and 77 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬Necroptosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬45. Necroptosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
47 | NOD-like receptor signaling pathway 💬 32 genes, 51 drugs (DrugBank) and 74 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬NOD-like receptor signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬47. NOD-like receptor signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
48 | NOD-like receptor signaling pathway 💬 32 genes, 51 drugs (DrugBank) and 74 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib Tofacitinib 💬NOD-like receptor signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬47. NOD-like receptor signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
49 | Non-small cell lung cancer 💬 21 genes, 40 drugs (DrugBank) and 58 diseases |
JAK3 [1] JAK3 💬Non-small cell lung cancer
|
Tofacitinib citrate Tofacitinib citrate 💬Non-small cell lung cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬49. Non-small cell lung cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
50 | Non-small cell lung cancer 💬 21 genes, 40 drugs (DrugBank) and 58 diseases |
JAK3 [1] JAK3 💬Non-small cell lung cancer
|
Tofacitinib Tofacitinib 💬Non-small cell lung cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬49. Non-small cell lung cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
51 | Osteoclast differentiation 💬 38 genes, 86 drugs (DrugBank) and 102 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Osteoclast differentiation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬51. Osteoclast differentiation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
52 | Osteoclast differentiation 💬 38 genes, 86 drugs (DrugBank) and 102 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib Tofacitinib 💬Osteoclast differentiation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬51. Osteoclast differentiation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
53 | Pancreatic cancer 💬 19 genes, 40 drugs (DrugBank) and 84 diseases |
JAK1 [1] JAK1 💬Pancreatic cancer
|
Tofacitinib citrate Tofacitinib citrate 💬Pancreatic cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬53. Pancreatic cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
54 | Pancreatic cancer 💬 19 genes, 40 drugs (DrugBank) and 84 diseases |
JAK1 [1] JAK1 💬Pancreatic cancer
|
Tofacitinib Tofacitinib 💬Pancreatic cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬53. Pancreatic cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
55 | Pathways in cancer 💬 111 genes, 222 drugs (DrugBank) and 146 diseases |
JAK1 [3] JAK1, JAK2, JAK3 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Pathways in cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬55. Pathways in cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
56 | Pathways in cancer 💬 111 genes, 222 drugs (DrugBank) and 146 diseases |
JAK1 [3] JAK1, JAK2, JAK3 💬
|
Tofacitinib Tofacitinib 💬Pathways in cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬55. Pathways in cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
57 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 35 genes, 66 drugs (DrugBank) and 100 diseases |
JAK1 [2] JAK1, JAK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬57. PD-L1 expression and PD-1 checkpoint pathway in cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
58 | PD-L1 expression and PD-1 checkpoint pathway in cancer 💬 35 genes, 66 drugs (DrugBank) and 100 diseases |
JAK1 [2] JAK1, JAK2 💬
|
Tofacitinib Tofacitinib 💬PD-L1 expression and PD-1 checkpoint pathway in cancer
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬57. PD-L1 expression and PD-1 checkpoint pathway in cancer
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
59 | PI3K-Akt signaling pathway 💬 85 genes, 142 drugs (DrugBank) and 131 diseases |
JAK1 [3] JAK1, JAK2, JAK3 💬
|
Tofacitinib citrate Tofacitinib citrate 💬PI3K-Akt signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬59. PI3K-Akt signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
60 | PI3K-Akt signaling pathway 💬 85 genes, 142 drugs (DrugBank) and 131 diseases |
JAK1 [3] JAK1, JAK2, JAK3 💬
|
Tofacitinib Tofacitinib 💬PI3K-Akt signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬59. PI3K-Akt signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
61 | Primary immunodeficiency 💬 17 genes, 47 drugs (DrugBank) and 39 diseases |
JAK3 [1] JAK3 💬Primary immunodeficiency
|
Tofacitinib citrate Tofacitinib citrate 💬Primary immunodeficiency
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬61. Primary immunodeficiency
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
62 | Primary immunodeficiency 💬 17 genes, 47 drugs (DrugBank) and 39 diseases |
JAK3 [1] JAK3 💬Primary immunodeficiency
|
Tofacitinib Tofacitinib 💬Primary immunodeficiency
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬61. Primary immunodeficiency
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
63 | Prolactin signaling pathway 💬 19 genes, 43 drugs (DrugBank) and 70 diseases |
JAK2 [1] JAK2 💬Prolactin signaling pathway
|
Tofacitinib citrate Tofacitinib citrate 💬Prolactin signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬63. Prolactin signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
64 | Prolactin signaling pathway 💬 19 genes, 43 drugs (DrugBank) and 70 diseases |
JAK2 [1] JAK2 💬Prolactin signaling pathway
|
Tofacitinib Tofacitinib 💬Prolactin signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬63. Prolactin signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
65 | Signaling pathways regulating pluripotency of stem cells 💬 21 genes, 36 drugs (DrugBank) and 62 diseases |
JAK1 [3] JAK1, JAK2, JAK3 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Signaling pathways regulating pluripotency of stem cells
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬65. Signaling pathways regulating pluripotency of stem cells
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
66 | Signaling pathways regulating pluripotency of stem cells 💬 21 genes, 36 drugs (DrugBank) and 62 diseases |
JAK1 [3] JAK1, JAK2, JAK3 💬
|
Tofacitinib Tofacitinib 💬Signaling pathways regulating pluripotency of stem cells
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬65. Signaling pathways regulating pluripotency of stem cells
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
67 | Th1 and Th2 cell differentiation 💬 46 genes, 51 drugs (DrugBank) and 77 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Th1 and Th2 cell differentiation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬67. Th1 and Th2 cell differentiation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
68 | Th1 and Th2 cell differentiation 💬 46 genes, 51 drugs (DrugBank) and 77 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬Th1 and Th2 cell differentiation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬67. Th1 and Th2 cell differentiation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
69 | Th17 cell differentiation 💬 56 genes, 80 drugs (DrugBank) and 108 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Th17 cell differentiation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬69. Th17 cell differentiation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
70 | Th17 cell differentiation 💬 56 genes, 80 drugs (DrugBank) and 108 diseases |
JAK1 [4] JAK1, JAK2, JAK3, TYK2 💬
|
Tofacitinib Tofacitinib 💬Th17 cell differentiation
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬69. Th17 cell differentiation
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
71 | Toll-like receptor signaling pathway 💬 41 genes, 65 drugs (DrugBank) and 79 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Toll-like receptor signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬71. Toll-like receptor signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
72 | Toll-like receptor signaling pathway 💬 41 genes, 65 drugs (DrugBank) and 79 diseases |
JAK1 [2] JAK1, TYK2 💬
|
Tofacitinib Tofacitinib 💬Toll-like receptor signaling pathway
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬71. Toll-like receptor signaling pathway
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
73 | Toxoplasmosis 💬 41 genes, 49 drugs (DrugBank) and 76 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Toxoplasmosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬73. Toxoplasmosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
74 | Toxoplasmosis 💬 41 genes, 49 drugs (DrugBank) and 76 diseases |
JAK1 [3] JAK1, JAK2, TYK2 💬
|
Tofacitinib Tofacitinib 💬Toxoplasmosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬73. Toxoplasmosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
75 | Tuberculosis 💬 66 genes, 73 drugs (DrugBank) and 98 diseases |
JAK1 [2] JAK1, JAK2 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Tuberculosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬75. Tuberculosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
76 | Tuberculosis 💬 66 genes, 73 drugs (DrugBank) and 98 diseases |
JAK1 [2] JAK1, JAK2 💬
|
Tofacitinib Tofacitinib 💬Tuberculosis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬75. Tuberculosis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
77 | Viral carcinogenesis 💬 32 genes, 31 drugs (DrugBank) and 58 diseases |
JAK1 [2] JAK1, JAK3 💬
|
Tofacitinib citrate Tofacitinib citrate 💬Viral carcinogenesis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬77. Viral carcinogenesis
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
78 | Viral carcinogenesis 💬 32 genes, 31 drugs (DrugBank) and 58 diseases |
JAK1 [2] JAK1, JAK3 💬
|
Tofacitinib Tofacitinib 💬Viral carcinogenesis
| Tofacitinib | 002 [22] 2 , 11, 35, 38, 39, 40, 44, 46, 49, 50, 51, 53, 65, 66, 84, 96, 97, 107, 110, 162, 271, 300 💬77. Viral carcinogenesis
|
Adipocytokine signaling pathway
16 genes, 38 drugs (DrugBank) and 104 diseases
AGE-RAGE signaling pathway in diabetic complications
28 genes, 55 drugs (DrugBank) and 96 diseases
Chemical carcinogenesis - receptor activation
39 genes, 135 drugs (DrugBank) and 134 diseases
Chemokine signaling pathway
23 genes, 38 drugs (DrugBank) and 64 diseases
Cholinergic synapse
32 genes, 64 drugs (DrugBank) and 81 diseases
Coronavirus disease - COVID-19
54 genes, 108 drugs (DrugBank) and 105 diseases
Efferocytosis
29 genes, 74 drugs (DrugBank) and 93 diseases
Epstein-Barr virus infection
67 genes, 90 drugs (DrugBank) and 82 diseases
Growth hormone synthesis, secretion and action
23 genes, 49 drugs (DrugBank) and 100 diseases
Hepatitis B
43 genes, 65 drugs (DrugBank) and 87 diseases
Hepatitis C
36 genes, 70 drugs (DrugBank) and 87 diseases
Herpes simplex virus 1 infection
70 genes, 80 drugs (DrugBank) and 107 diseases
Hormone signaling
66 genes, 211 drugs (DrugBank) and 153 diseases
Human cytomegalovirus infection
64 genes, 114 drugs (DrugBank) and 130 diseases
Human papillomavirus infection
51 genes, 106 drugs (DrugBank) and 115 diseases
Human T-cell leukemia virus 1 infection
59 genes, 74 drugs (DrugBank) and 96 diseases
Influenza A
65 genes, 78 drugs (DrugBank) and 98 diseases
JAK-STAT signaling pathway
61 genes, 113 drugs (DrugBank) and 123 diseases
Kaposi sarcoma-associated herpesvirus infection
60 genes, 94 drugs (DrugBank) and 118 diseases
Leishmaniasis
40 genes, 68 drugs (DrugBank) and 102 diseases
Lipid and atherosclerosis
51 genes, 71 drugs (DrugBank) and 103 diseases
Measles
42 genes, 63 drugs (DrugBank) and 68 diseases
Necroptosis
32 genes, 52 drugs (DrugBank) and 77 diseases
NOD-like receptor signaling pathway
32 genes, 51 drugs (DrugBank) and 74 diseases
Non-small cell lung cancer
21 genes, 40 drugs (DrugBank) and 58 diseases
Osteoclast differentiation
38 genes, 86 drugs (DrugBank) and 102 diseases
Pancreatic cancer
19 genes, 40 drugs (DrugBank) and 84 diseases
Pathways in cancer
111 genes, 222 drugs (DrugBank) and 146 diseases
PD-L1 expression and PD-1 checkpoint pathway in cancer
35 genes, 66 drugs (DrugBank) and 100 diseases
PI3K-Akt signaling pathway
85 genes, 142 drugs (DrugBank) and 131 diseases
Primary immunodeficiency
17 genes, 47 drugs (DrugBank) and 39 diseases
Prolactin signaling pathway
19 genes, 43 drugs (DrugBank) and 70 diseases
Signaling pathways regulating pluripotency of stem cells
21 genes, 36 drugs (DrugBank) and 62 diseases
Th1 and Th2 cell differentiation
46 genes, 51 drugs (DrugBank) and 77 diseases
Th17 cell differentiation
56 genes, 80 drugs (DrugBank) and 108 diseases
Toll-like receptor signaling pathway
41 genes, 65 drugs (DrugBank) and 79 diseases
Toxoplasmosis
41 genes, 49 drugs (DrugBank) and 76 diseases
Tuberculosis
66 genes, 73 drugs (DrugBank) and 98 diseases
Viral carcinogenesis
32 genes, 31 drugs (DrugBank) and 58 diseases